2 completed, 1 enrolling by invitation. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Enrolling by invitation 1 |
Follow Patrick Lao: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alzheimer's Disease Research Center (ADRC) PET Component Study 18F-MK6240, 18F-Florbetaben (FBB) - Alzheimer Disease, Mild Cognitive Impairment (MCI) | Phase 2 | Enrolling by invitation | Patrick Lao | 120 | 2026-08-06 | 2026-08-11 |
| Imaging Tau in Alzheimer's Disease and Normal Aging 18F-MK-6240, Lumbar Puncture (optional) - Alzheimer Disease | Phase 2 | Completed | Patrick Lao | 71 | 2017-12-11 | 2025-05-08 |
| Imaging Inflammation in Alzheimer's Disease 11C-PBR28, 18F-Florbetaben, Lumbar puncture (optional) - Alzheimer's Disease | Phase 2 | Completed | Patrick Lao | 60 | 2016-06-01 | 2025-03-05 |
Alzheimer Disease (3) · Cognitive Dysfunction (3) · Dementia (1) · Inflammation (1)
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (2) · Spinal Puncture (2) · (methyl-(11)C)N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine (1)
United States (3)
Patrick J Lao (1) · Patrick J Lao, PhD (1)
K23AG052633 (2), K24AG045334 (1), P30AG066462 (1), R01AG050440 (1), R01AG055299 (1), R56AG034189 (1)